Details of the Drug

General Information of Drug (ID: DM82Z30)

Drug Name
Topiramate
Synonyms
Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta
Indication
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Approved [1], [2], [3]
Epilepsy 8A60-8A68 Approved [1], [2], [3]
Seizure disorder 8A6Z Investigative [4]
Therapeutic Class
Anticonvulsants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 339.36
Topological Polar Surface Area (xlogp) -0.8
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-2 h [5]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [6]
Bioavailability
The bioavailability of drug is 64-90% [5]
Clearance
The renal clearance of drug is 17-18 mL/min [7]
Elimination
About 70-80% of the eliminated dose is found unchanged in the urine [8]
Half-life
The concentration or amount of drug in body reduced by one-half in 19 - 23 hours [7]
Metabolism
The drug is metabolized via reactions of glucuronidation, hydroxylation and hydrolysis [9]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.65423 micromolar/kg/day [10]
Unbound Fraction
The unbound fraction of drug in plasma is 0.72% [11]
Vd
The volume of distribution (Vd) of drug is 0.6-0.8 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 9.8 mg/mL [6]
Chemical Identifiers
Formula
C12H21NO8S
IUPAC Name
[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate
Canonical SMILES
CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C
InChI
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
InChIKey
KJADKKWYZYXHBB-XBWDGYHZSA-N
Cross-matching ID
PubChem CID
5284627
ChEBI ID
CHEBI:63631
CAS Number
97240-79-4
DrugBank ID
DB00273
TTD ID
D07VDZ
VARIDT ID
DR01372
INTEDE ID
DR1618
ACDINA ID
D00689

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor ionotropic kainate 1 (GRIK1) TT0MYE2 GRIK1_HUMAN Antagonist [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Topiramate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Topiramate caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [37]
Scopolamine DMOM8AL Major Additive CNS depression effects by the combination of Topiramate and Scopolamine. Addictive disorder [6C50-6C5Z] [38]
Mepyramine DMB4SFH Major Additive CNS depression effects by the combination of Topiramate and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [39]
Phenyltoloxamine DMKAEQW Major Increased risk of hyperpyrexia by the combination of Topiramate and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [39]
Tripelennamine DMZBU15 Major Increased risk of hyperpyrexia by the combination of Topiramate and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [38]
Hydroxyzine DMF8Y74 Major Additive CNS depression effects by the combination of Topiramate and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [38]
Promazine DMZAL7W Major Increased risk of hyperpyrexia by the combination of Topiramate and Promazine. Appearance/behaviour symptom [MB23] [38]
Desipramine DMT2FDC Major Additive CNS depression effects by the combination of Topiramate and Desipramine. Attention deficit hyperactivity disorder [6A05] [38]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Topiramate and Cariprazine. Bipolar disorder [6A60] [38]
Levomilnacipran DMV26S8 Moderate Antagonize the effect of Topiramate when combined with Levomilnacipran. Chronic pain [MG30] [40]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Topiramate and Olopatadine. Conjunctiva disorder [9A60] [41]
Ulipristal DMBNI20 Moderate Increased metabolism of Topiramate caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [37]
Mestranol DMG3F94 Moderate Increased metabolism of Topiramate caused by Mestranol mediated induction of CYP450 enzyme. Contraceptive management [QA21] [38]
Trimipramine DM1SC8M Major Additive CNS depression effects by the combination of Topiramate and Trimipramine. Depression [6A70-6A7Z] [38]
Cyclobenzaprine DM1YBRM Major Increased risk of hyperpyrexia by the combination of Topiramate and Cyclobenzaprine. Depression [6A70-6A7Z] [38]
Imipramine DM2NUH3 Major Additive CNS depression effects by the combination of Topiramate and Imipramine. Depression [6A70-6A7Z] [38]
Fluoxetine DM3PD2C Moderate Antagonize the effect of Topiramate when combined with Fluoxetine. Depression [6A70-6A7Z] [40]
Nortriptyline DM4KDYJ Major Increased risk of hyperpyrexia by the combination of Topiramate and Nortriptyline. Depression [6A70-6A7Z] [38]
Vilazodone DM4LECQ Moderate Antagonize the effect of Topiramate when combined with Vilazodone. Depression [6A70-6A7Z] [40]
Paroxetine DM5PVQE Moderate Antagonize the effect of Topiramate when combined with Paroxetine. Depression [6A70-6A7Z] [40]
Vortioxetine DM6F1PU Moderate Antagonize the effect of Topiramate when combined with Vortioxetine. Depression [6A70-6A7Z] [40]
Duloxetine DM9BI7M Moderate Antagonize the effect of Topiramate when combined with Duloxetine. Depression [6A70-6A7Z] [40]
Milnacipran DMBFE74 Moderate Antagonize the effect of Topiramate when combined with Milnacipran. Depression [6A70-6A7Z] [40]
Escitalopram DMFK9HG Moderate Antagonize the effect of Topiramate when combined with Escitalopram. Depression [6A70-6A7Z] [40]
Desvenlafaxine DMHD4PE Moderate Antagonize the effect of Topiramate when combined with Desvenlafaxine. Depression [6A70-6A7Z] [40]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Topiramate and OPC-34712. Depression [6A70-6A7Z] [38]
Clomipramine DMINRKW Major Increased risk of hyperpyrexia by the combination of Topiramate and Clomipramine. Depression [6A70-6A7Z] [38]
Amitriptyline DMK7F9S Major Additive CNS depression effects by the combination of Topiramate and Amitriptyline. Depression [6A70-6A7Z] [38]
Amoxapine DMKITQE Major Additive CNS depression effects by the combination of Topiramate and Amoxapine. Depression [6A70-6A7Z] [38]
Protriptyline DMNHTZI Major Increased risk of hyperpyrexia by the combination of Topiramate and Protriptyline. Depression [6A70-6A7Z] [38]
Doxepin DMPI98T Major Increased risk of hyperpyrexia by the combination of Topiramate and Doxepin. Depression [6A70-6A7Z] [39]
Maprotiline DMPWB7T Major Increased risk of hyperpyrexia by the combination of Topiramate and Maprotiline. Depression [6A70-6A7Z] [38]
Venlafaxine DMR6QH0 Moderate Antagonize the effect of Topiramate when combined with Venlafaxine. Depression [6A70-6A7Z] [40]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Topiramate and Esketamine. Depression [6A70-6A7Z] [42]
Hyoscyamine DM804UR Major Additive CNS depression effects by the combination of Topiramate and Hyoscyamine. Digestive system disease [DE2Z] [38]
Mepenzolate DM8YU2F Major Increased risk of hyperpyrexia by the combination of Topiramate and Mepenzolate. Digestive system disease [DE2Z] [38]
Oxybutynine DMJPBAX Major Increased risk of hyperpyrexia by the combination of Topiramate and Oxybutynine. Discovery agent [N.A.] [38]
Meclizine DMS7T13 Major Additive CNS depression effects by the combination of Topiramate and Meclizine. Dizziness and giddiness [MB48] [38]
Trihexyphenidyl DMB19L8 Major Additive CNS depression effects by the combination of Topiramate and Trihexyphenidyl. Dystonic disorder [8A02] [38]
Mephenytoin DM5UGDK Moderate Decreased metabolism of Topiramate caused by Mephenytoin. Epilepsy/seizure [8A61-8A6Z] [43]
Valproate DMCFE9I Moderate Increased risk of hyperammonemia by the combination of Topiramate and Valproate. Epilepsy/seizure [8A61-8A6Z] [43]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Topiramate caused by Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [43]
Ethotoin DMXWOCP Moderate Decreased metabolism of Topiramate caused by Ethotoin. Epilepsy/seizure [8A61-8A6Z] [43]
Carbamazepine DMZOLBI Moderate Increased metabolism of Topiramate caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Diphenhydramine DMKQTBA Major Additive CNS depression effects by the combination of Topiramate and Diphenhydramine. Episodic vestibular syndrome [AB31] [38]
Solifenacin DMG592Q Major Additive CNS depression effects by the combination of Topiramate and Solifenacin. Functional bladder disorder [GC50] [38]
Tolterodine DMSHPW8 Major Increased risk of hyperpyrexia by the combination of Topiramate and Tolterodine. Functional bladder disorder [GC50] [38]
Darifenacin DMWXLYZ Major Additive CNS depression effects by the combination of Topiramate and Darifenacin. Functional bladder disorder [GC50] [38]
Propantheline DM2EN6G Major Increased risk of hyperpyrexia by the combination of Topiramate and Propantheline. Gastric ulcer [DA60] [38]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Topiramate and Brimonidine. Glaucoma [9C61] [44]
Belladonna DM2RBWK Major Increased risk of hyperpyrexia by the combination of Topiramate and Belladonna. Infectious gastroenteritis/colitis [1A40] [38]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Topiramate and Propiomazine. Insomnia [7A00-7A0Z] [38]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Topiramate and ITI-007. Insomnia [7A00-7A0Z] [38]
Clidinium DMUMQZ0 Major Increased risk of hyperpyrexia by the combination of Topiramate and Clidinium. Irritable bowel syndrome [DD91] [38]
Dicyclomine DMZSDGX Major Additive CNS depression effects by the combination of Topiramate and Dicyclomine. Irritable bowel syndrome [DD91] [38]
Chloroquine DMSI5CB Moderate Antagonize the effect of Topiramate when combined with Chloroquine. Malaria [1F40-1F45] [42]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Topiramate when combined with Hydroxychloroquine. Malaria [1F40-1F45] [42]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Topiramate caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [38]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Topiramate and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [45]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Topiramate and Lasmiditan. Migraine [8A80] [46]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Topiramate and Flibanserin. Mood disorder [6A60-6E23] [47]
Doxylamine DMKOXFE Major Increased risk of hyperpyrexia by the combination of Topiramate and Doxylamine. Morning sickness disorder [SC00] [38]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Topiramate and Thalidomide. Multiple myeloma [2A83] [48]
Phenindamine DMDTC7R Major Additive CNS depression effects by the combination of Topiramate and Phenindamine. Nasopharyngitis [CA00] [38]
Dimenhydrinate DM264B3 Major Additive CNS depression effects by the combination of Topiramate and Dimenhydrinate. Nausea/vomiting [MD90] [38]
Prochlorperazine DM53SRA Major Increased risk of hyperpyrexia by the combination of Topiramate and Prochlorperazine. Nausea/vomiting [MD90] [38]
Promethazine DM6I5GR Major Additive CNS depression effects by the combination of Topiramate and Promethazine. Nausea/vomiting [MD90] [38]
Cyclizine DM9G7BS Major Additive CNS depression effects by the combination of Topiramate and Cyclizine. Nausea/vomiting [MD90] [38]
Thiethylperazine DMU3IET Major Increased risk of hyperpyrexia by the combination of Topiramate and Thiethylperazine. Nausea/vomiting [MD90] [38]
E-2007 DMJDYNQ Moderate Increased metabolism of Topiramate caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [37]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Topiramate and Apraclonidine. Optic nerve disorder [9C40] [44]
Dextropropoxyphene DM23HCX Major Decreased metabolism of Topiramate caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [49]
Flavoxate DMKV4NL Major Increased risk of hyperpyrexia by the combination of Topiramate and Flavoxate. Pain [MG30-MG3Z] [38]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Topiramate and Buprenorphine. Pain [MG30-MG3Z] [50]
Meperidine DMX4GND Moderate Additive CNS depression effects by the combination of Topiramate and Meperidine. Pain [MG30-MG3Z] [51]
Biperiden DME78OA Major Increased risk of hyperpyrexia by the combination of Topiramate and Biperiden. Parkinsonism [8A00] [38]
Procyclidine DMHFJDT Major Increased risk of hyperpyrexia by the combination of Topiramate and Procyclidine. Parkinsonism [8A00] [38]
Orphenadrine DMW542E Major Increased risk of hyperpyrexia by the combination of Topiramate and Orphenadrine. Parkinsonism [8A00] [38]
Methylscopolamine DM5VWOB Major Increased risk of hyperpyrexia by the combination of Topiramate and Methylscopolamine. Peptic ulcer [DA61] [38]
Levomepromazine DMIKFEL Major Increased risk of hyperpyrexia by the combination of Topiramate and Levomepromazine. Psychotic disorder [6A20-6A25] [38]
Fluphenazine DMIT8LX Major Additive CNS depression effects by the combination of Topiramate and Fluphenazine. Psychotic disorder [6A20-6A25] [38]
Triflupromazine DMKFQJP Major Increased risk of hyperpyrexia by the combination of Topiramate and Triflupromazine. Psychotic disorder [6A20-6A25] [38]
Cyproheptadine DM92AH3 Major Additive CNS depression effects by the combination of Topiramate and Cyproheptadine. Rheumatoid arthritis [FA20] [38]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Topiramate and Quetiapine. Schizophrenia [6A20] [38]
Mesoridazine DM2ZGAN Major Increased risk of hyperpyrexia by the combination of Topiramate and Mesoridazine. Schizophrenia [6A20] [38]
Thioridazine DM35M8J Major Additive CNS depression effects by the combination of Topiramate and Thioridazine. Schizophrenia [6A20] [38]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Topiramate and Aripiprazole. Schizophrenia [6A20] [38]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Topiramate and Iloperidone. Schizophrenia [6A20] [38]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Topiramate and Paliperidone. Schizophrenia [6A20] [38]
Loxapine DM8AI9U Major Additive CNS depression effects by the combination of Topiramate and Loxapine. Schizophrenia [6A20] [38]
Perphenazine DMA4MRX Major Increased risk of hyperpyrexia by the combination of Topiramate and Perphenazine. Schizophrenia [6A20] [38]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Topiramate and Molindone. Schizophrenia [6A20] [38]
Chlorpromazine DMBGZI3 Major Increased risk of hyperpyrexia by the combination of Topiramate and Chlorpromazine. Schizophrenia [6A20] [38]
Thiothixene DMDINC4 Major Increased risk of hyperpyrexia by the combination of Topiramate and Thiothixene. Schizophrenia [6A20] [38]
Clozapine DMFC71L Major Increased risk of hyperpyrexia by the combination of Topiramate and Clozapine. Schizophrenia [6A20] [38]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Topiramate and Trifluoperazine. Schizophrenia [6A20] [38]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Topiramate and Risperidone. Schizophrenia [6A20] [38]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Topiramate and Asenapine. Schizophrenia [6A20] [38]
Pimozide DMW83TP Major Increased risk of hyperpyrexia by the combination of Topiramate and Pimozide. Schizophrenia [6A20] [38]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Topiramate and Tizanidine. Tonus and reflex abnormality [MB47] [52]
Atropine DMEN6X7 Major Additive CNS depression effects by the combination of Topiramate and Atropine. Unspecific substance harmful effect [NE6Z] [38]
Chlorpheniramine DM5URA2 Major Additive CNS depression effects by the combination of Topiramate and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [38]
Triprolidine DM7SWIA Major Additive CNS depression effects by the combination of Topiramate and Triprolidine. Vasomotor/allergic rhinitis [CA08] [38]
Methdilazine DMAUHQX Major Increased risk of hyperpyrexia by the combination of Topiramate and Methdilazine. Vasomotor/allergic rhinitis [CA08] [38]
Clemastine DMBZWQL Major Increased risk of hyperpyrexia by the combination of Topiramate and Clemastine. Vasomotor/allergic rhinitis [CA08] [38]
Carbinoxamine DMCT31R Major Increased risk of hyperpyrexia by the combination of Topiramate and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [38]
Trimeprazine DMEMV9D Major Increased risk of hyperpyrexia by the combination of Topiramate and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [39]
Brompheniramine DMFOVSD Major Increased risk of hyperpyrexia by the combination of Topiramate and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [38]
Dexbrompheniramine DMKVWGE Major Additive CNS depression effects by the combination of Topiramate and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [38]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Topiramate and Cetirizine. Vasomotor/allergic rhinitis [CA08] [53]
Acrivastine DMTIGA0 Major Increased risk of hyperpyrexia by the combination of Topiramate and Acrivastine. Vasomotor/allergic rhinitis [CA08] [38]
Azatadine DMZ80SB Major Additive CNS depression effects by the combination of Topiramate and Azatadine. Vasomotor/allergic rhinitis [CA08] [38]
Disopyramide DM5SYZP Major Additive CNS depression effects by the combination of Topiramate and Disopyramide. Ventricular tachyarrhythmia [BC71] [38]
⏷ Show the Full List of 113 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Oleic acid E00421 445639 Emulsifying agent; Penetration agent; Solubilizing agent
Quinoline yellow WS E00309 24671 Colorant
Riboflavin E00422 493570 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Medium-chain triglyceride E00640 Not Available Emollient; Lubricant; Surfactant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sorbitan monolaurate E00508 11046239 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 43 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Topiramate 50 mg capsule 50 mg 24 HR Extended Release Oral Capsule Oral
Topiramate 100 mg capsule 100 mg 24 HR Extended Release Oral Capsule Oral
Topiramate 200 mg capsule 200 mg 24 HR Extended Release Oral Capsule Oral
Topiramate 25 mg capsule 25 mg 24 HR Extended Release Oral Capsule Oral
Topiramate 100 mg capsule 100 mg Sprinkle 24 HR Extended Release Oral Capsule Oral
Topiramate 200 mg capsule 200 mg Sprinkle 24 HR Extended Release Oral Capsule Oral
Topiramate 150 mg capsule 150 mg Sprinkle 24 HR Extended Release Oral Capsule Oral
Topiramate 25 mg capsule 25 mg Sprinkle 24 HR Extended Release Oral Capsule Oral
Topiramate 50 mg capsule 50 mg Sprinkle 24 HR Extended Release Oral Capsule Oral
Topiramate 15 mg capsule 15 mg Oral Capsule Oral
Topiramate 25 mg capsule 25 mg Oral Capsule Oral
Topiramate 100 mg tablet 100 mg Oral Tablet Oral
Topiramate 200 mg tablet 200 mg Oral Tablet Oral
Topiramate 25 mg tablet 25 mg Oral Tablet Oral
Topiramate 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6849).
2 Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs. 2008;10(4):217-54.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5 Knauf H, Mutschler E: Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet. 1998 Jan;34(1):1-24. doi: 10.2165/00003088-199834010-00001.
6 BDDCS applied to over 900 drugs
7 Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41 Suppl 1:S61-5.
8 Walker MC, Sander JW: Topiramate: a new antiepileptic drug for refractory epilepsy. Seizure. 1996 Sep;5(3):199-203.
9 Murrell GA, Rapeport WG: Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet. 1986 Sep-Oct;11(5):343-53. doi: 10.2165/00003088-198611050-00001.
10 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
11 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
12 Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43.
13 The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res. 2009 Nov;26(11):2464-70.
14 Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003 Dec;44(12):1521-8.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
25 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
26 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
27 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
28 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
29 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
30 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
31 Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60.
32 The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9.
33 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
35 Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.
36 Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
37 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38 Product Information. Topamax (topiramate). Ortho Pharmaceutical Corporation, Raritan, NJ.
39 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
40 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
41 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
42 Cerner Multum, Inc. "Australian Product Information.".
43 Bourgeois BF "Drug interaction profile of topiramate." Epilepsia 37(suppl 2 (1996): s14-7. [PMID: 8641241]
44 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
45 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
46 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
47 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
48 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
49 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
50 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
51 Lambertsen CJ, Wendel H, Longenhagen JB "The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2." J Pharmacol Exp Ther 131 (1961): 381-93. [PMID: 13758472]
52 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
53 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.